---
title: "Adial Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Vassiliki Economides"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303813186.md"
description: "Adial Pharmaceuticals CFO Vassiliki Economides filed an initial beneficial ownership statement disclosing stock options to purchase 307,814 common shares at $5.76 per share."
datetime: "2026-10-31T00:36:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303813186.md)
  - [en](https://longbridge.com/en/news/303813186.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303813186.md)
generator: "portal-rs"
---

# Adial Pharmaceuticals Files Initial Beneficial Ownership Statement for CFO Vassiliki Economides

-   Adial Pharmaceuticals Chief Financial Officer Vassiliki Economides disclosed stock options to buy 307,814 common shares at $5.76 in an initial ownership filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-114575), on October 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ADIL.US](https://longbridge.com/en/quote/ADIL.US.md)
- [AZR.US](https://longbridge.com/en/quote/AZR.US.md)

## Related News & Research

- [Adial Pharmaceuticals delays shareholder meeting vote on proposals 3-6 to Oct. 15 pending Nasdaq approval](https://longbridge.com/en/news/300824661.md)
- [Coastlands Capital LP reports Adial Pharmaceuticals common share purchase worth $32,613.87](https://longbridge.com/en/news/292502856.md)
- [Adial Pharmaceuticals Removes Penalty Provisions in PIPE and Note Exchange to Restore Nasdaq Compliance](https://longbridge.com/en/news/299236328.md)
- [Adial Q2 net loss widens to $51.99 million from year-ago quarter](https://longbridge.com/en/news/295970963.md)
- [Major Investor Quietly Boosts Stake in Adial Pharmaceuticals](https://longbridge.com/en/news/291495678.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**